GlassScriptPhysician profile
Michael Meir Goldman
NPI 1912220666
$2,066.08
in general payments reported to CMS, 2019-2025
12 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $197 · 2021: $416 · 2022: $288 · 2023: $563 · 2024: $242 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.47 |
| Education | $281.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $756.69 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $525.90 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $355.20 | 2019-2024 | Veltassa |
| Mallinckrodt Hospital Products INC. | $121.73 | 2023-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $91.33 | 2023-2025 | |
| Amgen INC. | $75.65 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $28.24 | 2019 | |
| Horizon Therapeutics Plc | $26.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.08 | 2024 | Jardiance |
| Recor Medical INC | $20.34 | 2025 | Paradise Ultrasound Renal Denervation System |
| Csl Behring | $20.12 | 2023 | Kcentra |
| Akebia Therapeutics INC | $19.16 | 2025 | Vafseo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.